Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis
- 31 December 1993
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 29, S22-S29
- https://doi.org/10.1016/s0959-8049(05)80256-4
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694British Journal of Cancer, 1988
- BRL 43694: A Novel Antiemetic to Prevent Nausea and Vomiting Induced by ChemotherapyJNCI Journal of the National Cancer Institute, 1988
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- On the receiving end—patient perception of the side-effects of cancer chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1983
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981
- Cancer Treatment Needs Better AntiemeticsNew England Journal of Medicine, 1975
- Effects of metoclopramide on isolated guinea-pig colon. 2)Interference with ganglionic stimulant drugsEuropean Journal of Pharmacology, 1970